Jehad Charo

3.5k total citations · 1 hit paper
49 papers, 2.7k citations indexed

About

Jehad Charo is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Jehad Charo has authored 49 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Immunology, 24 papers in Oncology and 15 papers in Molecular Biology. Recurrent topics in Jehad Charo's work include Immunotherapy and Immune Responses (27 papers), Immune Cell Function and Interaction (19 papers) and CAR-T cell therapy research (14 papers). Jehad Charo is often cited by papers focused on Immunotherapy and Immune Responses (27 papers), Immune Cell Function and Interaction (19 papers) and CAR-T cell therapy research (14 papers). Jehad Charo collaborates with scholars based in Sweden, United States and Germany. Jehad Charo's co-authors include Rolf Kiessling, Thomas Blankenstein, Birgitta Agerberth, Lennart Lindbom, Farah Idali, Joachim Werr, Hans Jörnvall, Guðmundur H. Guðmundsson, Hans Wigzell and Berit Olsson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Jehad Charo

49 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The human antimicrobial and chemotactic peptides LL-37 and α-defensins are expressed by specific lymphocyte and monocyte populations

2000 615 citations Jehad Charo, Rolf Kiessling et al. profile →

Peers

Countries citing papers authored by Jehad Charo

Since Specialization

Citations

This map shows the geographic impact of Jehad Charo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jehad Charo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jehad Charo more than expected).

Fields of papers citing papers by Jehad Charo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jehad Charo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jehad Charo. The network helps show where Jehad Charo may publish in the future.

Co-authorship network of co-authors of Jehad Charo

This figure shows the co-authorship network connecting the top 25 collaborators of Jehad Charo. A scholar is included among the top collaborators of Jehad Charo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jehad Charo. Jehad Charo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Machine learning identifies clinical tumor mutation landscape pathways of resistance to checkpoint inhibitor therapy in NSCLC 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Bruno Gomès, James J. Cai, Jehad Charo	4
2	Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors 2024 ·Clinical Cancer Research ·Neeltje Steeghs, Carlos Gomez‐Roca, Kristoffer Staal Rohrberg, Morten Mau‐Sørensen, Debbie Robbrecht, Josep Tabernero, (unknown), María E. Rodríguez-Ruiz, (unknown), Daniela Schmid, (unknown), Carl Watson, (unknown), David Dejardin, Stefan Evers, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Ignacio Melero	11
3	A Composite Decision Rule of CD8+ T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials 2023 ·Clinical Cancer Research ·David Dejardin, Anton Kraxner, Annika Blank, Natascha Rieder, Volker Teichgräber, Nicolas Städler, Ulrich Beyer, Bruno Gomès, Jehad Charo	4
4	Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data 2023 ·Journal for ImmunoTherapy of Cancer ·(unknown), David Dejardin, Eva Rossmann, Jehad Charo	20
5	Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy 2018 ·Clinical Cancer Research ·Benjamin Ribba, Christophe Boetsch, Tapan K. Nayak, Hans Peter Grimm, Jehad Charo, Stefan Evers, Christian Klein, Jean Tessier, (unknown), Alex Phipps, Pavel Pisa, Volker Teichgräber	56
6	Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies 2017 ·Genome Medicine ·Ryan J. Hartmaier, Jehad Charo, David Fabrizio, Michael E. Goldberg, Lee A. Albacker, William Pao, Juliann Chmielecki	42
7	Preventing tumor escape by targeting a post-proteasomal trimming independent epitope 2016 ·The Journal of Experimental Medicine ·Ana Textor, (unknown), Peter‐M. Kloetzel, Bianca Weißbrich, Cynthia Pérez, Jehad Charo, (unknown), John Sidney, Alessandro Sette, Ton N. Schumacher, Christin Keller, Dirk H. Busch, Ulrike Seifert, Thomas Blankenstein	20
8	Efficacy of CAR T-cell Therapy in Large Tumors Relies upon Stromal Targeting by IFNγ 2014 ·Cancer Research ·Ana Textor, (unknown), (unknown), Cynthia Pérez, Anna Kruschinski, Markus Chmielewski, Hinrich Abken, Thomas Blankenstein, Jehad Charo	58
9	Oncogene-Targeting T Cells Reject Large Tumors while Oncogene Inactivation Selects Escape Variants in Mouse Models of Cancer 2011 ·Cancer Cell ·(unknown), (unknown), Andreas Herrmann, (unknown), Christoph Loddenkemper, Thomas Kammertoens, Peter T. Daniel, Hua Yu, Jehad Charo, Thomas Blankenstein	34
10	Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial 2010 ·Journal of Translational Medicine ·Håkan Norell, Isabel Poschke, Jehad Charo, (unknown), Courtney L. Erskine, Marie P. Piechocki, Keith L. Knutson, Jonas Bergh, Elisabet Lidbrink, Rolf Kiessling	99
11	In Vivo Imaging of an Inducible Oncogenic Tumor Antigen Visualizes Tumor Progression and Predicts CTL Tolerance 2010 ·The Journal of Immunology ·(unknown), Jehad Charo, (unknown), Christoph Loddenkemper, (unknown), (unknown), Cynthia Pérez, Gerald Willimsky, Thomas Blankenstein	12
12	Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas 2008 ·Proceedings of the National Academy of Sciences ·Anna Kruschinski, Andreas Moosmann, Isabel Poschke, Håkan Norell, Markus Chmielewski, Barbara Seliger, Rolf Kiessling, Thomas Blankenstein, Hinrich Abken, Jehad Charo	158
13	HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice 2008 ·Cancer Immunology Immunotherapy ·Simona Vertuani, (unknown), (unknown), Jehad Charo, Håkan Norell, François A. Lemonnier, Pavel Pisa, Barbara Seliger, Rolf Kiessling	48
14	A Synthetic Peptide Homologous to Functional Domain of Human IL-10 Down-Regulates Expression of MHC Class I and Transporter Associated with Antigen Processing 1/2 in Human Melanoma Cells 2004 ·The Journal of Immunology ·Mónica Kurte, Mercedes López, Adam Aguirre, Alejandro Escobar, Juan Carlos Aguillón, Jehad Charo, Christian Grønhøj, Rolf Kiessling, Flavio Salazar‐Onfray	58
15	Induction of PSA‐specific CTLs and anti‐tumor immunity by a genetic prostate cancer vaccine 2004 ·The Prostate ·Anna‐Karin Roos, Maxim Pavlenko, Jehad Charo, Lars Egevad, Pavel Pisa	42
16	Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines 2003 ·International Journal of Cancer ·Aniruddha Choudhury, Jehad Charo, Sunil K. Parapuram, Richard C. Hunt, D. Margaret Hunt, Barbara Seliger, Rolf Kiessling	127
17	Targeting of Human Dendritic Cells by Autologous NK Cells 1999 ·The Journal of Immunology ·Julia L. Wilson, (unknown), Jehad Charo, Annika Scheynius, Maria-Teresa Bejarano, Hans‐Gustaf Ljunggren	149
18	NK Cell Triggering by the Human Costimulatory Molecules CD80 and CD86 1999 ·The Journal of Immunology ·Julia L. Wilson, Jehad Charo, Alfonso Martin‐Fontecha, Paolo Dellabona, Giulia Casorati, Benedict J. Chambers, Rolf Kiessling, (unknown), Hans‐Gustaf Ljunggren	91
19	A Long-Term Memory Obtained by Genetic Immunization Results in Full Protection from a Mammary Adenocarcinoma Expressing an EBV Gene 1999 ·The Journal of Immunology ·Jehad Charo, (unknown), (unknown), Pankaj Trivedi, George Klein, Jorma Hinkula, Rolf Kiessling	16
20	Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes 1998 ·International Journal of Cancer ·(unknown), Rongcun Yang, Jehad Charo, Fumiko Ichihara, Esteban Celis, Alessandro Sette, Ettore Appella, Takayoshi Sekikawa, Yoshirô Matsumoto, Rolf Kiessling	78

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact